Profusa Inc. (NASDAQ:PFSA) shares rose in Monday premarket trading after the company announced a $30 million Letter of Intent.

The company plans to acquire BioInsights LLC’s PanOmics multi-omics diagnostics platform. The move expands Profusa into precision diagnostics and advances its path to commercialization.

Transaction Highlights

The proposed all-equity deal would grant Profusa exclusive rights to the PanOmics platform and related know-how.

The transaction will add $30 million to its balance sheet shareholder equity.

BioInsights will receive a 3% royalty, provide clinical samples, and retain the right to nominate one independent board member. The transaction remains subject to due diligence, shareholder approval, and customary closing conditions.

Accelerated Commercialization Pathway

Profusa said integrating PanOmics with its Lumee platform will enable faster development of lab-developed tests. This is driven by access to clinically annotated samples and established assay infrastructure.

The combined platform is expected to support multi-indication diagnostics, real-time monitoring, and data-driven clinical tools.

Pancreatic Cancer Focus and Strategic Context

The company is advancing a Mayo Clinic collaboration targeting pancreatic cancer, using its oxygen monitoring technology for intraoperative and postoperative applications. Profusa estimates the U.S. market includes about 13,000 annual procedures, representing a $26 million opportunity.

CEO Dr. Ben Hwang called the deal “a pivotal step” toward building a scalable precision diagnostics platform, adding that the PanOmics platform and Mayo Clinic collaboration position the company to accelerate development, drive clinical adoption, and generate near-term growth.

“The combination of the PanOmics platform and our collaboration with Mayo Clinic positions us to build a differentiated, scalable presence in precision diagnostics and surgical monitoring. The entry into pancreatic cancer is instrumental in our establishing a platform capable of supporting multiple indications and long-term growth.”

Company Context

Profusa is a clinical-stage digital health and medical technology company focused on biosensing solutions. Its technologies aim to improve patient health outcomes across various diseases and conditions.

The company develops bioengineered sensors that continuously transmit actionable, clinical-grade data for medical and personal use.

This recent expansion into molecular diagnostics through the acquisition of the PanOmics platform is crucial for Profusa as it aims to establish a scalable presence in precision diagnostics.

The collaboration with Mayo Clinic further enhances its credibility and growth potential in the healthcare market.

PFSA Price Action: Profusa shares were up 134.99% at $1.78 during premarket trading on Monday, according to Benzinga Pro data.

Photo via Shutterstock